A Multi-center, Randomized, Double-blind, Placebo-controlled, Therapeutic Exploratory, Phase II Clinical Trial for the Efficacy Investigation and Safety Evaluation of DWP708 for Treating Rash Acneiform

All the patients had Grade ≥2 ERSEs according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) v. 5.0

Inclusion Criteria:

1. Age: older than 19
2. Eastern Cooperative Oncology Group (ECOG) performance status 0 -2
3. Patients who have Rash acneiform Gr≥2 (NCI CTCAE v5.0)
4. Patients who are currently administering EGFR TKI or EGFR mAb

Exclusion Criteria:

1. Known allergies, hypersensitivity, or intolerance to study drugs, chemotherapy drugs using this clinical trial

2. Patients with a history of topical medication

   • Steroids within 3 days prior to baseline visit
   • Antihistamine, Antipruritic agents, Antibiotics agents within 1 week prior to baseline visit
   • Tacrolimus, Pimecrolimus within 2 weeks prior to baseline visit